IMMUNIC (IMUX) director receives 445,000 stock options at $11.60 exercise price

Rhea-AI Filing Summary

IMMUNIC, INC. director Daniel Vitt received a grant of stock options covering 445,000 shares of common stock as equity compensation. The options have an exercise price of $11.60 per share and expire on April 2, 2036, with all 445,000 options shown as held directly after the grant.

The grant was conditionally approved by the Board of Directors and became effective only after stockholders approved an amendment to the company’s 2019 Omnibus Equity Incentive Plan at the 2026 Annual Meeting held on June 29, 2026. The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the following thirty-six months, tying director compensation to longer-term company performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Vitt Daniel

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	445,000	$0.00	--

Holdings After Transaction: Stock Option — 445,000 shares (Direct, null)

Footnotes (1)

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026. The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

Key Figures

Stock options granted: 445,000 options Exercise price: $11.60 per share Options held after grant: 445,000 options +4 more

7 metrics

Stock options granted 445,000 options Director grant covering common stock

Exercise price $11.60 per share Strike price for option grant

Options held after grant 445,000 options Total derivative holdings from this grant

Expiration date April 2, 2036 Option term end date

Initial vesting tranche 25% Vests on April 2, 2027

Remaining vesting period 36 months Monthly vesting after April 2, 2027

Annual meeting approval date June 29, 2026 Shareholders approved plan amendment

Key Terms

Stock Option, 2019 Omnibus Equity Incentive Plan, Annual Meeting of Stockholders, vest

4 terms

Stock Option financial

"Represents options to purchase shares of common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

2019 Omnibus Equity Incentive Plan financial

"subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan"

Annual Meeting of Stockholders regulatory

"obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026"

vest financial

"The shares underlying this option vest 25% on April 2, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/29/2026 - 04:31 PM Accepted by SEC EDGAR 06/29/2026 - 04:31 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Vitt Daniel

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$11.6	06/29/2026		A		445,000(1)		(2)	04/02/2036	Common Stock	445,000	$0.00	445,000	D

Explanation of Responses:

1. Represents options to purchase shares of common stock conditionally approved by the Board of Directors, subject to approval of an amendment to the Company's 2019 Omnibus Equity Incentive Plan, as amended, by the Company's stockholders, which approval was obtained at the Company's 2026 Annual Meeting of Stockholders held on June 29, 2026.

2. The shares underlying this option vest 25% on April 2, 2027, and the remainder vest in equal increments on each successive one-month anniversary thereafter for the next thirty-six months.

	/s/ Daniel Vitt	06/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did IMMUNIC (IMUX) director Daniel Vitt report on this Form 4?

IMMUNIC director Daniel Vitt reported receiving a grant of stock options for 445,000 shares of common stock. The options are compensation-related, not an open-market purchase, and give him the right to buy shares at a fixed exercise price over time if vesting conditions are met.

What are the key terms of Daniel Vitt’s 445,000 IMMUNIC (IMUX) stock options?

The grant covers 445,000 shares with an exercise price of $11.60 per share and an expiration date of April 2, 2036. These terms define the cost to exercise the options and the final date by which they must be exercised to receive shares.

How do Daniel Vitt’s IMMUNIC (IMUX) options vest over time?

The options vest 25% on April 2, 2027, with the remaining 75% vesting in equal monthly installments over the next thirty-six months. This creates a four-year vesting schedule, encouraging continued board service and alignment with longer-term company performance.

Were IMMUNIC (IMUX) shareholders involved in approving these stock options?

Yes. The options were conditionally approved by the Board, subject to shareholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan. That shareholder approval was obtained at IMMUNIC’s 2026 Annual Meeting of Stockholders held on June 29, 2026, enabling the grant.

Is the IMMUNIC (IMUX) Form 4 transaction a market buy or sell of shares?

No. The Form 4 reports a grant of stock options as compensation, coded as an acquisition (code A), not an open-market purchase or sale. Vitt gains the right to buy shares later at $11.60, subject to vesting and future exercise decisions.

How many IMMUNIC (IMUX) derivative securities does Daniel Vitt hold after this grant?

Following the reported transaction, Vitt holds 445,000 stock options directly, according to the filing. This reflects the new grant amount and shows his full derivative position from this grant, which can convert into common shares if exercised after vesting.